{"success":true,"data":{"pressRelease":{"id":"3294","rtpr_id":"nNFC2xzNFt","ticker":"CORT","exchange":"NASDAQ","all_tickers":["CORT"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","published_at":"2026-04-21T16:00:13.770Z","article_body":"New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Corcept Therapeutics\nIncorporated (NASDAQ: CORT) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Corcept securities between\nOctober 31, 2024 and December 30, 2025, both dates inclusive (the \"Class\nPeriod\"). Such investors are encouraged to join this case by visiting the\nfirm's site: bgandg.com/CORT\n(https://api.newsfilecorp.com/redirect/wEZEWUBz8x).\n\nCorcept Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n(1) Defendants overstated the strength of the clinical trials supporting\nrelacorilant by representing them as \"powerful support\" for Corcept's New Drug\nApplication (\"NDA\") to the U.S. Food and Drug Administration (\"FDA\");\n(2) Defendants falsely conveyed confidence in relacorilant's regulatory\nprospects by claiming they had communicated with the FDA, foresaw no\nimpediments to approval, and repeatedly told investors that \"relacorilant is\napproaching approval,\" when, in fact, the FDA had repeatedly raised concerns\nregarding the adequacy of the clinical evidence supporting the NDA; and\n(3) as a result of the foregoing, Defendants failed to disclose the known and\nmaterial risk that Corcept's relacorilant NDA would not be approved, rendering\ntheir statements about the Company's business, operations, and prospects\nmaterially false and misleading at all relevant times.\n\nWhat's Next for Corcept Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/CORT\n(https://api.newsfilecorp.com/redirect/gJwJOI5rpP), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Corcept you\nhave until April 21, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Corcept Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Corcept Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/0pZpVtkOaN), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/RYKY7TOEno), X\n(https://api.newsfilecorp.com/redirect/WAEA0hMgeE), Facebook\n(https://api.newsfilecorp.com/redirect/qpwp8tKjOY), or Instagram\n(https://api.newsfilecorp.com/redirect/noEoVSMVoK).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/292470","article_body_html":"","raw_payload":{"data":{"id":"nNFC2xzNFt","title":"Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","ticker":"CORT","created":"2026-04-21T16:00:13.770Z","tickers":["CORT"],"exchange":"NASDAQ","article_body":"New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Corcept Therapeutics\nIncorporated (NASDAQ: CORT) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Corcept securities between\nOctober 31, 2024 and December 30, 2025, both dates inclusive (the \"Class\nPeriod\"). Such investors are encouraged to join this case by visiting the\nfirm's site: bgandg.com/CORT\n(https://api.newsfilecorp.com/redirect/wEZEWUBz8x).\n\nCorcept Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n(1) Defendants overstated the strength of the clinical trials supporting\nrelacorilant by representing them as \"powerful support\" for Corcept's New Drug\nApplication (\"NDA\") to the U.S. Food and Drug Administration (\"FDA\");\n(2) Defendants falsely conveyed confidence in relacorilant's regulatory\nprospects by claiming they had communicated with the FDA, foresaw no\nimpediments to approval, and repeatedly told investors that \"relacorilant is\napproaching approval,\" when, in fact, the FDA had repeatedly raised concerns\nregarding the adequacy of the clinical evidence supporting the NDA; and\n(3) as a result of the foregoing, Defendants failed to disclose the known and\nmaterial risk that Corcept's relacorilant NDA would not be approved, rendering\ntheir statements about the Company's business, operations, and prospects\nmaterially false and misleading at all relevant times.\n\nWhat's Next for Corcept Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/CORT\n(https://api.newsfilecorp.com/redirect/gJwJOI5rpP), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Corcept you\nhave until April 21, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Corcept Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Corcept Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/0pZpVtkOaN), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/RYKY7TOEno), X\n(https://api.newsfilecorp.com/redirect/WAEA0hMgeE), Facebook\n(https://api.newsfilecorp.com/redirect/qpwp8tKjOY), or Instagram\n(https://api.newsfilecorp.com/redirect/noEoVSMVoK).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/292470"},"type":"article","timestamp":"2026-04-21T16:00:13.835927558Z","server_sent_at_ms":1776787213835},"received_at":"2026-04-21T16:00:13.891Z","source_url":"https://www.newsfilecorp.com/release/292470"},"analysis":{"id":"2193","press_release_id":"3294","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Allegations of overstating clinical trial support for relacorilant NDA","Allegations of failure to disclose FDA concerns regarding clinical evidence"],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC announced that a class action lawsuit has been filed against Corcept Therapeutics for alleged violations of federal securities laws.\n\nThe complaint alleges that the company made materially false statements regarding the strength of clinical trials for relacorilant and failed to disclose concerns raised by the FDA regarding the NDA.\n\nThe class period covers securities purchased between October 31, 2024 and December 30, 2025, with a lead plaintiff deadline set for April 21, 2026.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Securities fraud class action targets Corcept over alleged misrepresentation of relacorilant's clinical data and FDA interactions."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["relacorilant"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff counsel"},{"name":"Corcept Therapeutics Incorporated","ticker":"CORT","relationship":"defendant"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"A class action lawsuit has been filed alleging securities fraud related to the company's primary asset, relacorilant, claiming misrepresentation of clinical trial strength and regulatory risks."},"tickerRelevance":{"others":[],"primary":"CORT"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"Bronstein, Gewirtz & Grossman, LLC announced that a class action lawsuit has been filed against Corcept Therapeutics for alleged violations of federal securities laws.\n\nThe complaint alleges that the company made materially false statements regarding the strength of clinical trials for relacorilant and failed to disclose concerns raised by the FDA regarding the NDA.\n\nThe class period covers securities purchased between October 31, 2024 and December 30, 2025, with a lead plaintiff deadline set for April 21, 2026.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["relacorilant"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff counsel"},{"name":"Corcept Therapeutics Incorporated","ticker":"CORT","relationship":"defendant"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T22:13:37.015Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.626Z"}},"durationMs":55619,"modelName":"glm-4.7"}}